Eli Lilly’s Mounjaro cuts risk of developing Type 2 diabetes, study finds

Date:

August 20, 2024

Eli Lilly’s stock gained more than 2% premarket on Tuesday after the drugmaker said that tirzepatide, marketed as the diabetes drug Mounjaro and weight-loss treatment Zepbound, sharply cut patients’ risk of developing Type 2 diabetes in a late-stage trial.

Source link

Brett explodes as Bitcoin Dogs eyes top crypto exchange listings

Moise Bombito's transfer to Nice completes meteoric rise for Canada's Copa America star

Alexandra Williams

Alexandra Williams is a writer and editor. Angeles. She writes about politics, art, and culture for LinkDaddy News.

Eli Lilly’s Mounjaro cuts risk of developing Type 2 diabetes, study finds

Recent posts

Cava is riding a strong wave, but the stock’s quadrupling in 2024 has analysts wary

Oil prices on track for 4th straight weekly gain

The Fed is likely to cut interest rates until next summer as the threat of inflation fades

U.S. Steel’s stock up 2% after offering strong guidance and confidence Nippon deal can close by year-end

Money is the ‘tip of the iceberg’ in assessing big donors’ political influence, study finds

Home Depot’s stock drops as higher rates hurt spending on home improvement

Adobe sued by U.S. regulators for making it too difficult to cancel subscriptions

Investors question Fed’s rate cut amid signs of faster economic growth

Cost of shorting Carl Icahn company’s stock has spiked since billionaire’s SEC settlement

Mohawk Industries’ stock rallies as flooring-products maker draws upgrade on boosted profit view

Echoes of U.K.’s 2022 bond crisis weigh on Treasury market ahead of U.S. election

This biotech’s stock could double if its treatment for major depressive disorder succeeds, says Mizuho

Bitcoin is trading at record high near $85,000. Is it a good time to buy?

AI chip startup Cerebras files for IPO, in market dominated by Nvidia

Harris sees ‘next generation of breakthroughs’ built by U.S. workers. AI, crypto could benefit.

Related articles

Stock market ‘finally paying more attention to tariffs’ as a potential headwind

Investors are bracing for higher-for-even-longer interest rates

RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.

Manufacturing activity surges in New York region to highest level in nearly three years

RFK Jr. would rattle health markets as head of HHS, but his confirmation is far from certain, analyst says

Vaccine-maker stocks like Moderna, Pfizer drop as Trump picks RFK Jr. to lead HHS

Powell says Fed doesn’t need to hurry to cut interest rates

Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug

Company

Follow us